Shield insists merger deal with Axis is underway
This article was originally published in Clinica
Executive Summary
Shield Diagnostics maintains that the deal to merge with homocysteine test rival Axis Biochemicals is still on, despite persistent rumours in the UK national press that adverse reaction from the Norwegian company's major shareholders may yet scupper the deal.